Replies to post #27473 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Opportunity, If you read about shorting, the hedge funds can make money during substantial swings in the stock price. They short on peaks and cover when the price falls back. The stock have been 5 to 6 cents for months all the while Mata hari has been claiming massive continued shorting. Even if they were shorting, they just cannot make money that way.

You and I can not short stocks because we do not have necessary broker cooperation to short any stocks. I have never shorted any stocks but I have read the rules for shorting and the brokerage I use will not allow shorting a stock selling for less than $5. Other brokerages have lower limits but none will allow a private holder to short a 5 cent stock.

I do agree with you that Moro even beginning clinical trials for FDA approval would give the stock a shot in the arm. The problem I see is that it is not going to be an inexpensive effort. There is only one thing that will send the stock upward without a following retreat. That is revenue. Moro must show a source of revenue that could take the company to profitability.

I think that Moro understands that spending money to obtain FDA approval is not a guarantee of substantial revenue. Moro needs the licensees to sell the product and all indications are that Inverness and Abbott are not progressing. Moro could spend a bunch of money obtaining approval and still not have any effective marketing and no revenue. He said he was going to license the ELISA test 2 1/2 years ago and there have been ZERO licensees signed.

Look at RPC. Management got the stock price up with a lot of no cost licensees but IMO, it is poised for a huge fall. There is just no way they are going to have the necessary sales to meet their estimates.

[Gold Seeker]

Opportunity, you can see from the below quotes that Moro apparently has changed his mind about BioCurex performing clinical trials and seeking FDA approval. He wants the partners or licensees to be responsible for FDA approval.

From the latest 10Q:

"Our business model is to develop internally our RECAF cancer diagnostic
platform to the stage where individual applications can be partnered or licensed
in strategic relationships for regulatory approval and commercialization. Our
objective is to receive cash from licensing fees, milestone payments, and
royalties from such partnerships which support continued development of our
cancer diagnostic portfolio. We have signed licensing agreements for its cancer
detection blood tests with Abbott Laboratories and with Inverness Medical
Innovations. In the veterinarian market where there are no regulatory hurdles,
our objective is to commercialize our technology through our subsidiary, OncoPet
Diagnostics, and with distributors in North America, Europe and elsewhere.

Our principal objectives for the twelve-month period ending June 30, 2011
are as follows:

o grant one additional license for our cancer detection blood test;
o commercialize veterinary applications of RECAF testing technology through our wholly-owned subsidiary, OncoPet Diagnostics;
o finish development for our rapid, point of care cancer test; and
o commercialize other test formats through our wholly-owned subsidiary in China, BioCurex China Co., Ltd."

From the 10K back in March:

"Our principal objectives for the twelve months ending March 31, 2011 are as follows:

o grant one additional semi-exclusive license for testing blood samples using automated testing equipment;

o commercialize veterinary applications not requiring regulatory approvals;

o finish developing a POC rapid format test for the doctor's office, bedside and veterinary use;

o conduct clinical trials and seek FDA approval for marketing of the POC rapid format test; and

o commercialize manual testing formats, principally in large cities in foreign countries where further regulatory clearance is not required.